Literature DB >> 10537317

Biological activities and signaling pathways of the granulin/epithelin precursor.

T Zanocco-Marani1, A Bateman, G Romano, B Valentinis, Z H He, R Baserga.   

Abstract

Growth-regulated cells, such as 3T3 mouse embryo fibroblasts (MEFs), require more than one growth factor for growth, usually the insulin-like growth factor I (IGF-I) in combination with either platelet-derived growth factor or epidermal growth factor. Singly, these growth factors cannot sustain the growth of 3T3 cells. However, if the IGF-I receptor (IGF-IR) is even modestly overexpressed, then IGF-I, by itself, stimulates the growth of MEFs in monolayer and makes them capable of forming colonies in soft agar. The granulin/epithelin precursor (GEP) has been identified as the only growth factor, thus far, that can stimulate by itself the growth of R- cells, a 3T3-like cell line in which the genes for the IGF-IR have been deleted. We have expressed GEP in R- cells and show that these cells can now grow in serum-free medium. GEP, however, cannot replace other functions of the IGF-IR, such as protection from apoptosis (anoikis) or transforming activity (colony formation in soft agar). GEP activates, in R- cells, the two signaling pathways that are known to be sufficient for IGF-I-mediated mitogenesis in cells overexpressing the IGF-IR, the mitogen-activated protein kinase and the phosphatidylinositol 3-kinase pathways. This may explain why GEP, by itself, can replace the IGF-IR for growth in monolayer cultures. It also confirms that, for transformation, other pathways must be activated besides the two pathways that are sufficient for mitogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537317

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  83 in total

Review 1.  The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.

Authors:  John R Finnerty; Wang-Xia Wang; Sébastien S Hébert; Bernard R Wilfred; Guogen Mao; Peter T Nelson
Journal:  J Mol Biol       Date:  2010-08-01       Impact factor: 5.469

2.  Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein.

Authors:  Fengjin Guo; Yongjie Lai; Qingyun Tian; Edward A Lin; Li Kong; Chuanju Liu
Journal:  Arthritis Rheum       Date:  2010-07

Review 3.  Progranulin: a growth factor, a novel TNFR ligand and a drug target.

Authors:  Chuan-ju Liu; Xavier Bosch
Journal:  Pharmacol Ther       Date:  2011-10-08       Impact factor: 12.310

4.  Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism.

Authors:  Gabriel Frampton; Pietro Invernizzi; Francesca Bernuzzi; Hae Yong Pae; Matthew Quinn; Darijana Horvat; Cheryl Galindo; Li Huang; Matthew McMillin; Brandon Cooper; Lorenza Rimassa; Sharon DeMorrow
Journal:  Gut       Date:  2011-11-07       Impact factor: 23.059

Review 5.  The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.

Authors:  Konstanze F Winklhofer; Jörg Tatzelt; Christian Haass
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

6.  Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth.

Authors:  Giada Monami; Velia Emiliozzi; Alessandro Bitto; Francesca Lovat; Shi-Qiong Xu; Silvia Goldoni; Matteo Fassan; Ginette Serrero; Leonard G Gomella; Raffaele Baffa; Renato V Iozzo; Andrea Morrione
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Progranulin: a novel regulator of gastrointestinal cancer progression.

Authors:  Sharon Demorrow
Journal:  Transl Gastrointest Cancer       Date:  2013-07

Review 8.  Progranulin: A key player in autoimmune diseases.

Authors:  Jinlong Jian; Guangfei Li; Aubryanna Hettinghouse; Chuanju Liu
Journal:  Cytokine       Date:  2016-08-12       Impact factor: 3.861

9.  Increased serum GP88 (Progranulin) concentrations in rheumatoid arthritis.

Authors:  Yasuko Yamamoto; Masao Takemura; Ginette Serrero; Jun Hayashi; Binbin Yue; Aya Tsuboi; Hisako Kubo; Takashi Mitsuhashi; Kenji Mannami; Masao Sato; Hidetoshi Matsunami; Yushi Matuo; Kuniaki Saito
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

10.  IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program.

Authors:  Xiang Li; Paul E Massa; Adedayo Hanidu; Gregory W Peet; Patrick Aro; Ann Savitt; Sheenah Mische; Jun Li; Kenneth B Marcu
Journal:  J Biol Chem       Date:  2002-09-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.